2011
Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities,
Munshi N, Lee S, Kambhampati S, Rose M, Mohiuddin A, Efebera Y, Han A, Houranieh A, Zimelman A, Brophy M, Prabhala R, Grady T, Mehta P, Hayes T, Yellapragada S, Behler C, Klein C, Roodman D, Lichtenstein A. Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities,. Blood 2011, 118: 3964. DOI: 10.1182/blood.v118.21.3964.3964.Peer-Reviewed Original ResearchOverall response rateNewly diagnosed multiple myeloma patientsEntity's Board of DirectorsGrade 2 neuropathyMultiple myeloma patientsSignificant co-morbiditiesCo-morbiditiesMyeloma patientsOlder patientsEvaluate overall response rateAutologous stem cell transplantationGrade 1 neuropathyGrade 3 neuropathyStem cell transplantationProportion of patientsSingle-arm studyHistory of cancerAssociated with toxicityAdvisory CommitteeVeterans HospitalWeekly bortezomibBortezomib doseDexamethasone regimenWeekly regimenDexamethasone doseEfficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study.
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Grady T, Klein C, Mehta P, Hayes T, Roodman G, Lichtenstein A. Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. Journal Of Clinical Oncology 2011, 29: 8074-8074. DOI: 10.1200/jco.2011.29.15_suppl.8074.Peer-Reviewed Original Research
2010
Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Saba H, Klein C, Mehta P, Hayes T, Roodman D, Lichtenstein A. Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities. Blood 2010, 116: 3061. DOI: 10.1182/blood.v116.21.3061.3061.Peer-Reviewed Original ResearchEntity's Board of DirectorsGrade 1 neuropathyMultiple myeloma patientsSignificant co-morbiditiesOverall response rateCo-morbiditiesMyeloma patientsNewly-diagnosed multiple myeloma patientsNewly diagnosed multiple myeloma patientsEvaluate overall response rateAutologous stem cell transplantationElevation of serum creatinineResponse rateGrade 3 neuropathyRegimen of bortezomibDose of bortezomibAssociated with side effectsStem cell transplantationImproved toxicity profileProportion of patientsOlder patient populationHistory of cancerAdvisory CommitteeWeekly bortezomibBortezomib dose